Scholar 1 Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scholar 1 Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scholar 1 Study Today - Breaking & Trending Today

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

Published: June 28, 2023

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Source: onclive.com

Related Topics:

Little RockUnited StatesUniversity Of ArkansasAakash MukherjeeDepartment Of Internal MedicineCollege Of MedicineWinthropp Rockefeller Cancer InstituteWinthropp Rockefeller Cancer Institute Transplant CenterCancer Institute Transplant CenterCancer InstituteMedical SciencesInternal MedicineContributing KiteRelapsed Refractoryb Cell LymphomaPatients With Relapsed Refractory Diffuse Largeb Cell LymphomaScholar 1 StudyZuma 1 TrialAxicabtagene CiloleucelZuma 7 TrialTransform TrialWinthropp Rockefeller Cancer Institute At The University Of Arkansas For Medical Sciences Uams College Of Medicine